

TABLE OF CONTENTS

1	OVERVIEW OF THE IMPAACT NETWORK.....	1-1
1.1	Background of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network.....	1-1
1.2	IMPAACT Mission and Scientific Agenda	1-2
1.3	IMPAACT Network Organization.....	1-4
1.4	IMPAACT Operational Policies	1-5
1.5	Governmental Organizations Involved in IMPAACT Research	1-6
2	NETWORK GROUPS.....	2-1
2.1	Network Leadership	2-1
2.2	Advisory Groups	2-5
2.3	Central Resources	2-6
2.4	Oversight Groups.....	2-12
2.5	Protocol Teams.....	2-13
2.6	Clinical Research Sites	2-13
3	GOOD DOCUMENTATION PRACTICE.....	3-1
3.1	Introduction to Good Documentation Practices within the IMPAACT Network.....	3-1
3.2	General Guidelines for Document Creation, Review, and Management.....	3-2
4	PROTOCOL TEAMS.....	4-1
4.1	Protocol Chair and Vice Chair.....	4-1
4.2	Protocol Team.....	4-3
4.3	Relationship of Protocol Team to IMPAACT Management Oversight Group (MOG)	4-8
4.4	Conflict Resolution within Protocol Teams.....	4-9
5	COMMUNITY PARTICIPATION AND ENGAGEMENT IN THE IMPAACT NETWORK	5-1
5.1	Confidentiality	5-1
5.2	IMPAACT Community Advisory Board (ICAB).....	5-2
5.3	ICAB Leadership Group (ILG).....	5-4
5.4	IMPAACT Site Community Advisory Boards.....	5-8

5.5	Community Input into the Protocol Development Process	5-8
5.6	Cross Network Collaborations and Community Partners	5-9
6	NETWORK MEETINGS AND COMMUNICATIONS	6-1
6.1	Meetings	6-1
6.2	Communication Mechanisms and Material Distribution	6-2
6.3	Release of Information to the Public	6-4
7	IMPAACT GENERAL POLICIES AND PROCEDURES: FUNDING, CONFLICT OF INTEREST, CERTIFICATE OF CONFIDENTIALITY, AND CLINICALTRIALS.GOV	7-1
7.1	IMPAACT Funding Procedures	7-1
7.2	Conflict of Interest and Financial Disclosure Policies	7-3
7.3	NIH Certificate of Confidentiality	7-5
7.4	Processes for Registration and Results Entry for IMPAACT Studies in ClinicalTrials.gov	7-6
7.5	Letters of Support	7-8
8	HUMAN SUBJECTS CONSIDERATIONS	8-1
8.1	Applicable US Federal Regulations and Guidelines	8-1
8.2	Training Requirements: Good Clinical Practice and Human Subjects Protection	8-2
8.3	IRB/EC Review and Approval	8-3
8.4	Other Regulatory Entities	8-5
8.5	Informed Consent and Assent	8-5
8.6	Special Populations	8-10
8.7	Confidentiality	8-13
8.8	Participant Costs for Study Participation	8-13
8.9	Participant Reimbursement for Study Participation	8-14
8.10	Access to HIV-Related Care	8-14
8.11	Local Reporting Requirements	8-14
9	PROTOCOL DEVELOPMENT AND MODIFICATIONS	9-1
9.1	Concept Development and Review	9-3
9.2	Protocol Development and Review	9-5
9.3	Protocol Modifications	9-12
9.4	Co-Endorsed and Co-Development of Protocols and Other Networks' Studies	9-17

10	SITE SELECTION FOR IMPAACT STUDIES	10-1
10.1	Initial Site Selection for New Studies	10-1
10.2	Addition of Sites During Accrual of Ongoing Studies	10-4
10.3	Expansion Beyond the IMPAACT Network Affiliated Sites	10-4
11	STUDY-SPECIFIC PRE-IMPLEMENTATION ACTIVITIES: OPEN TO ACCRUAL AND SITE-SPECIFIC STUDY ACTIVATION	11-1
11.1	Study Open to Accrual Requirements.....	11-2
11.2	Site-Specific Study Activation	11-10
12	STUDY IMPLEMENTATION.....	12-1
12.1	Participant Accrual	12-1
12.2	Follow-Up Visits	12-3
12.3	Data Collection.....	12-6
12.4	Study Team Communications	12-11
12.5	Protocol Deviations	12-17
13	STUDY OVERSIGHT.....	13-1
13.1	On-Site Clinical Quality Management	13-1
13.2	Clinical Site Monitoring.....	13-2
13.3	Protocol Team Monitoring	13-2
13.4	IMPAACT Leadership Oversight.....	13-3
13.5	IMPAACT Study Monitoring Committee Review	13-4
13.6	Sponsor Oversight	13-10
13.7	Data and Safety Monitoring Board Reviews.....	13-10
14	SITE STUDY-SPECIFIC CLOSE-OUT	14-1
14.1	Overview, Key Principles, and Definitions.....	14-1
14.2	Timeline for Study Close-Out.....	14-2
14.3	Study Close-Out Communications and Considerations for Sites	14-5
15	ANCILLARY STUDIES, INVESTIGATIONS, AND ACCESS TO STUDY DATA	15-1
15.1	Scope and Definitions	15-1
15.2	Responsibilities and Procedures for Development and Review of Ancillary Studies	15-3
15.3	Special Considerations for Proposals Requiring Genetic Analyses	15-6

15.4	Specimen and Data Usage Agreements (SDUA).....	15-7
15.5	Responsibilities and Procedures for Completion of Ancillary Studies	15-8
15.6	Publications Resulting from Data Requests	15-9
15.7	Procedures for Access to Study Data During Trial Conduct and After Trial Completion	15-9
16	TRAINING	16-1
16.1	Human Subjects Protection (HSP) Training	16-3
16.2	Good Clinical Practice Training	16-3
16.3	Laboratory Related Training.....	16-4
16.4	Data Management Training.....	16-5
16.5	Research Ethics Training for Community Representatives	16-5
16.6	Study-Specific Training	16-6
16.7	Documenting Training	16-10
17	Laboratory Considerations	17-1
17.1	IMPAACT Laboratory Center	17-1
17.2	IMPAACT Laboratories	17-4
17.3	Protocol-Specified Testing	17-5
17.4	IMPAACT Laboratory Network Requirements: US Laboratories.....	17-5
17.5	IMPAACT Laboratory Network Requirements: Non-US Laboratories.....	17-6
17.6	Laboratory Data Management System (LDMS)	17-12
17.7	Data Corrections	17-12
17.8	External Quality Assurance (EQA) Participation and Proficiency Testing Providers.....	17-13
17.9	Peripheral Blood Mononuclear Cell (PBMC) Separation and Cryopreservation	17-15
17.10	Mycobacterium Tuberculosis Quality Assessment (TBQA) Program	17-15
17.11	Testing Backup Plans	17-15
17.12	Instrument and Method Validation	17-16
17.13	Management and Testing Plans	17-18
17.14	Shipping Capabilities.....	17-18
17.15	Specimen Shipping	17-18
17.16	Specimen Destruction	17-20
17.17	National Approval Requirements and Material Transfer Agreements	17-21
17.18	IMPAACT Quality Assessment Monitoring.....	17-21
17.19	Introduction of Novel/Non-Standard Analytes into IMPAACT Studies	17-22

17.20	Changes in Laboratory Personnel.....	17-24
17.21	Laboratory Relocation	17-24
17.22	Additional Resources	17-25
18	NETWORK EVALUATION	18-1
18.1	Network Evaluation Plan and Performance Measures.....	18-2
18.2	Performance Criteria for IMPAACT-affiliated NIAID-funded Clinical Research Sites.....	18-3
18.3	Overall Network Productivity	18-6
18.4	Outcomes and Actions	18-6
19	PUBLICATIONS REQUIREMENTS AND PROCEDURES	19-1
19.1	Overview, Key Principles, and Definitions.....	19-1
19.2	Preparation, Review, and Completion of Analyses	19-5
19.3	Development and Review of Manuscripts.....	19-9
19.4	Tracking of Manuscript Preparation	19-18
19.5	IMPAACT Manuscript Review Process	19-18
19.6	Journal Submission.....	19-19
19.7	Authorship.....	19-20
19.8	Acknowledgements.....	19-22
19.9	Public Access Policy	19-22
19.10	Abstracts.....	19-23
19.11	Communications Plans and Dissemination of Study Results.....	19-24
19.12	Publication Costs	19-26
19.13	Concluding a Study.....	19-26
	APPENDIX I - UNBLINDING PROCEDURES.....	I-1
I.1	Purpose.....	I-1
I.2	Scope.....	I-1
I.3	Definitions	I-1
I.4	Roles and Responsibilities	I-2
I.5	Reasons and Guidelines for Unblinding.....	I-6
I.6	Procedures.....	I-9
I.7	References.....	I-11
I.8	Questions.....	I-11